Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug crawled date : 2022 - 09 - 06 save search
Disease-Modifying Antirheumatic Drug (DMARD) Market to Surpass US$ 27,167.8 Million by 2030 - Coherent Market Insights
Published: 2022-09-06 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.02%
H: 0.0%
C: 0.0%
UCBJY | $64.535 -4.38% 3.5K
|
Manufacturing
|
| O: 0.73%
H: 2.28%
C: 1.72%
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.65%
H: 0.93%
C: 0.71%
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.03%
H: 1.18%
C: 0.13%
ABBV | News | $167.89 0.89% 0.0% 5.6M
|
Health Technology
|
| O: -0.03%
H: 1.08%
C: 0.84%
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
GILD | $66.95 0.29% 0.28% 5.6M
|
Health Technology
|
| O: 0.44%
H: 2.03%
C: 1.76%
CPIX | $1.6 6.02% 2.2K
|
Health Technology
|
| O: -4.52%
H: 7.12%
C: 5.69%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: 0.24%
H: 1.04%
C: 0.82%
drug market
Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction
Published: 2022-09-06 (Crawled : 18:00) - biospace.com/
TNYA | $4.45 3.01% 2.92% 300K
|
|
| O: 4.17%
H: 0.77%
C: -10.95%
tn-301 fda clearance drug heart application therapeutics study
Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader– Phase 1/2 Clinical Trial in Patients with MYC-driven Solid Tumors Expected to Dose in Q4 2022 –
Published: 2022-09-06 (Crawled : 18:00) - biospace.com/
GLUE | $5.55 -5.13% -5.41% 120K
|
Professional, Scientific, and T...
|
| O: 3.72%
H: 1.43%
C: -2.51%
mrt-2359 fda clearance drug rosa application expected trial therapeutics molecular
Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate
Published: 2022-09-06 (Crawled : 13:00) - globenewswire.com
PSTV | News | $1.58 -3.07% -3.16% 200K
|
Health Technology
|
| O: -1.16%
H: 0.61%
C: -11.11%
fda drug candidate meeting therapeutics plus
Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Published: 2022-09-06 (Crawled : 13:00) - prnewswire.com
MBRX | $4.45 -4.3% -4.49% 17K
|
Health Technology
|
| O: 0.0%
H: 1.66%
C: -3.5%
wp1122 treatment fda designation drug glioblastoma
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
Published: 2022-09-06 (Crawled : 12:20) - globenewswire.com
SPRO | $1.405 0.36% 0.36% 290K
|
Health Technology
|
| O: 14.94%
H: 127.46%
C: 35.28%
drug meeting program therapeutics food update
U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2022-09-06 (Crawled : 12:00) - prnewswire.com
SNGX | $0.408 -5.34% -5.64% 620K
|
Health Technology
|
| O: 1.38%
H: 1.38%
C: -5.47%
treatment awards drug grant t-cell food study
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.